Buy Tirzepatide 20mg: Dual GIP/GLP-1 Agonist for Metabolic Research

Tirzepatide (20mg) is a potent dual GIP and GLP-1 receptor agonist widely studied for its effects on type 2 diabetes, obesity, insulin sensitivity, appetite regulation, weight loss, and cardiovascular health. This 20mg research vial provides a versatile mid-range strength ideal for dose-response studies, titration experiments, and medium-term metabolic research.

Molecular Formula: C225H348N48O68 Molecular Weight: 4813.527 g/mol Purity: ≥99% (lyophilized, research-grade)

Important Notice: This peptide is strictly intended for research and laboratory use only. Not for human consumption, diagnostic, therapeutic, or veterinary purposes. Please review and agree to our Terms and Conditions before ordering.

What is Tirzepatide?

Tirzepatide is a synthetic polypeptide that functions as a dual agonist targeting both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This unique dual mechanism allows it to deliver stronger effects on glucose control and body weight reduction compared to single-incretin therapies.

In major research programs (SURPASS and SURMOUNT trials), tirzepatide has shown impressive dose-dependent improvements in HbA1c and body weight. The 20mg strength is commonly used in studies exploring effective maintenance dosing and metabolic outcomes.

Mechanism of Action in Research

Tirzepatide activates dual incretin pathways to:

• Promote glucose-dependent insulin secretion
• Suppress glucagon release
• Slow gastric emptying for prolonged satiety
• Reduce appetite and food intake through central nervous system effects
• Enhance insulin sensitivity and lipid metabolism

This combined GIP/GLP-1 action results in superior glycemic control and substantial fat mass reduction in experimental models.

Key Research Findings and Benefits

Glycemic Control

Studies report significant HbA1c reductions (up to -2.3% to -2.46%) and improved insulin sensitivity at higher doses.

Weight Loss and Obesity

Tirzepatide has demonstrated average body weight reductions of up to ~21% over 72 weeks in obesity models, with strong effects on visceral fat loss.

Cardiovascular Support

Research highlights improvements in blood pressure, lipid profiles (lower triglycerides/LDL, higher HDL), and potential cardiometabolic benefits.

Research Applications

The 20mg vial is ideal for:

• Dose-response and titration studies
• Medium-term metabolic and obesity models
• Glycemic control and insulin sensitivity research
• Comparative dual-agonist experiments
• Body composition and fat mass analysis

Reconstitution is typically performed with bacteriostatic water for flexible laboratory dosing.

Why Choose 99% Pure Tirzepatide 20mg?

Our Tirzepatide 20mg provides ≥99% purity for reliable, reproducible results in receptor activation, insulin dynamics, and metabolic endpoint studies. Third-party tested and lyophilized for maximum stability.

In summary, Tirzepatide 20mg is a versatile dual GIP/GLP-1 agonist peptide for advanced research into type 2 diabetes, obesity, weight loss, insulin sensitivity, and cardiometabolic health. Advance your metabolic studies with this high-quality research tool.